Literature DB >> 32259060

Oxycodone-Mediated Activation of the Mu Opioid Receptor Reduces Whole Brain Functional Connectivity in Mice.

Md Taufiq Nasseef1, Jai Puneet Singh1, Aliza T Ehrlich1, Michael McNicholas1, Da Woon Park1, Weiya Ma1, Praveen Kulkarni2, Brigitte L Kieffer1, Emmanuel Darcq1.   

Abstract

Oxycodone is a potent medicinal opioid analgesic to treat pain. It is also addictive and a main cause for the current opioid crisis. At present, the impact of oxycodone on coordinated brain network activities, and contribution of the mu opioid receptor (MOR) to these effects, is unknown. We used pharmacological magnetic resonance imaging in mice to characterize MOR-mediated oxycodone effects on whole-brain functional connectivity (FC). Control (CTL) and MOR knockout (KO) animals were imaged under dexmedetomidine in a 7Tesla scanner. Acquisition was performed continuously before and after 2 mg/kg oxycodone administration (analgesic in CTL mice). Independent component analysis (data-driven) produced a correlation matrix, showing widespread oxycodone-induced reduction of FC across 71 components. Isocortex, nucleus accumbens (NAc), pontine reticular nucleus, and periacqueducal gray (PAG) components showed the highest number of significant changes. Seed-to-voxel FC analysis (hypothesis-driven) was then focused on PAG and NAc considered key pain and reward centers. The two seeds showed reduced FC with 8 and 22 Allen Brain Atlas-based regions, respectively, in CTL but not KO mice. Further seed-to-seed quantification showed highest FC modifications of both PAG and NAc seeds with hypothalamic and amygdalar areas, as well as between them, revealing the strongest impact across reward and aversion/pain centers of the brain. In conclusion, we demonstrate that oxycodone reduces brain communication in a MOR-dependent manner, and establish a preliminary whole-brain FC signature of oxycodone. This proof-of-principle study provides a unique platform and reference data set to test other MOR opioid agonists and perhaps discover new mechanisms and FC biomarkers predicting safer analgesics.
Copyright © 2019 American Chemical Society.

Entities:  

Year:  2019        PMID: 32259060      PMCID: PMC7088903          DOI: 10.1021/acsptsci.9b00021

Source DB:  PubMed          Journal:  ACS Pharmacol Transl Sci        ISSN: 2575-9108


  52 in total

Review 1.  Functional magnetic resonance imaging in rodents: an unique tool to study in vivo pharmacologic neuromodulation.

Authors:  Elisabeth Jonckers; Annemie Van der Linden; Marleen Verhoye
Journal:  Curr Opin Pharmacol       Date:  2013-07-12       Impact factor: 5.547

Review 2.  The prescription opioid and heroin crisis: a public health approach to an epidemic of addiction.

Authors:  Andrew Kolodny; David T Courtwright; Catherine S Hwang; Peter Kreiner; John L Eadie; Thomas W Clark; G Caleb Alexander
Journal:  Annu Rev Public Health       Date:  2015-01-12       Impact factor: 21.981

3.  Endogenous opioid-dopamine neurotransmission underlie negative CBV fMRI signals.

Authors:  Yen-Yu I Shih; Yun-Chen Chiang; Bai-Chuang Shyu; Fu-Shan Jaw; Timothy Q Duong; Chen Chang
Journal:  Exp Neurol       Date:  2012-01-05       Impact factor: 5.330

Review 4.  Oxycodone.

Authors:  Eija Kalso
Journal:  J Pain Symptom Manage       Date:  2005-05       Impact factor: 3.612

5.  Intravenous oxycodone, hydrocodone, and morphine in recreational opioid users: abuse potential and relative potencies.

Authors:  William W Stoops; Kevin W Hatton; Michelle R Lofwall; Paul A Nuzzo; Sharon L Walsh
Journal:  Psychopharmacology (Berl)       Date:  2010-07-28       Impact factor: 4.530

Review 6.  Regulation of μ-opioid receptors: desensitization, phosphorylation, internalization, and tolerance.

Authors:  John T Williams; Susan L Ingram; Graeme Henderson; Charles Chavkin; Mark von Zastrow; Stefan Schulz; Thomas Koch; Christopher J Evans; Macdonald J Christie
Journal:  Pharmacol Rev       Date:  2013-01-15       Impact factor: 25.468

7.  Parallel buprenorphine phMRI responses in conscious rodents and healthy human subjects.

Authors:  Lino Becerra; Jaymin Upadhyay; Pei-Ching Chang; James Bishop; Julie Anderson; Richard Baumgartner; Adam J Schwarz; Alexandre Coimbra; Diana Wallin; Lauren Nutile; Edward George; Gary Maier; Soujanya Sunkaraneni; Smriti Iyengar; Jeffrey L Evelhoch; David Bleakman; Richard Hargreaves; David Borsook
Journal:  J Pharmacol Exp Ther       Date:  2013-01-31       Impact factor: 4.030

8.  Effect of intracarotid and intraventricular morphine on regional cerebral blood flow and metabolism in pentobarbital-anesthetized dogs.

Authors:  P J Hoehner; J T Whitson; J R Kirsch; R J Traystman
Journal:  Anesth Analg       Date:  1993-02       Impact factor: 5.108

Review 9.  Does the pharmacology of oxycodone justify its increasing use as an analgesic?

Authors:  Klaus T Olkkola; Vesa K Kontinen; Teijo I Saari; Eija A Kalso
Journal:  Trends Pharmacol Sci       Date:  2013-03-04       Impact factor: 14.819

10.  Expression map of 78 brain-expressed mouse orphan GPCRs provides a translational resource for neuropsychiatric research.

Authors:  Aliza T Ehrlich; Grégoire Maroteaux; Anne Robe; Lydie Venteo; Md Taufiq Nasseef; Leon C van Kempen; Naguib Mechawar; Gustavo Turecki; Emmanuel Darcq; Brigitte L Kieffer
Journal:  Commun Biol       Date:  2018-08-06
View more
  5 in total

1.  Chronic generalized pain disrupts whole brain functional connectivity in mice.

Authors:  Md Taufiq Nasseef; Weiya Ma; Jai Puneet Singh; Naoki Dozono; Kevin Lançon; Philippe Séguéla; Emmanuel Darcq; Hiroshi Ueda; Brigitte L Kieffer
Journal:  Brain Imaging Behav       Date:  2021-01-11       Impact factor: 3.978

2.  Targeting Morphine-Responsive Neurons: Generation of a Knock-In Mouse Line Expressing Cre Recombinase from the Mu-Opioid Receptor Gene Locus.

Authors:  Julie Bailly; Natalie Del Rossi; Léonie Runtz; Jing-Jing Li; DaWoon Park; Grégory Scherrer; Arnaud Tanti; Marie-Christine Birling; Emmanuel Darcq; Brigitte L Kieffer
Journal:  eNeuro       Date:  2020-05-29

Review 3.  Recent advances in basic science methodology to evaluate opioid safety profiles and to understand opioid activities.

Authors:  Aliza T Ehrlich; Emmanuel Darcq
Journal:  Fac Rev       Date:  2021-02-19

4.  The utility of maraviroc, an antiretroviral agent used to treat HIV, as treatment for opioid abuse? Data from MRI and behavioural testing in rats.

Authors:  Sade C Iriah; Catarina Borges; Uri Shalev; Xuezhu Cai; Dan Madularu; Praveen P Kulkarni; Craig F Ferris
Journal:  J Psychiatry Neurosci       Date:  2021-09       Impact factor: 6.186

Review 5.  Oxycodone in the Opioid Epidemic: High 'Liking', 'Wanting', and Abuse Liability.

Authors:  Cherkaouia Kibaly; Jacob A Alderete; Steven H Liu; Hazem S Nasef; Ping-Yee Law; Christopher J Evans; Catherine M Cahill
Journal:  Cell Mol Neurobiol       Date:  2020-11-27       Impact factor: 4.231

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.